Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Probiotic MR-61 in Delaying Myopia Progression
NCT07298824Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MR-61 in myopia (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Change in Spherical Equivalent Refraction at 25 months. Started Dec 2025; status: recruiting.
02
Drugs
MR-61
03
Conditions
myopia
Beyond the preview
Go deeper on NCT07298824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298824.